BioBridgeX
Log inCompare quotes
Modality

Microbiome / Live Biotherapeutic CRO and CDMO vendors

2 qualified vendorsFree for buyersNeutral vendor of record
Quick answer

Developing a microbiome or live biotherapeutic product means outsourcing strain isolation and characterization, anaerobic culturing, microbiome and metagenomic analysis, GLP toxicology, and live-cell GMP manufacturing with viability and potency assays few generalist CDMOs can run. BioBridgeX is a neutral vendor of record, free for buyers, that matches you with qualified specialist CROs and CDMOs under one contract.

Microbiome / Live Biotherapeutic CRO and CDMO vendors (2)

Esco Aster

Unclaimed · public records

CDMO · Viral Vector Manufacturing, Plasmid DNA Manufacturing, Cell Therapy Manufacturing

Viral Vector ManufacturingPlasmid DNA ManufacturingCell Therapy ManufacturingOncologyInfectious DiseaseGene Therapy (AAV / Viral Vector)Plasmid DNA

Wacker Biotech

Unclaimed · public records

CDMO · Process Development, Analytical Development, Drug Substance: Biologics

Process DevelopmentAnalytical DevelopmentDrug Substance: BiologicsInfectious DiseaseImmunology & InflammationProtein / Enzyme (Recombinant)Vaccine

What does it take to develop and manufacture a Microbiome / Live Biotherapeutic drug?

Microbiome and live biotherapeutic products (LBPs) break the usual drug-development mold because the active ingredient is alive. Whether your candidate is a single defined strain, a rationally designed consortium, or a donor-derived community, the program runs on bacteriology and anaerobic handling rather than the synthesis and purification logic that governs small molecules or antibodies. That difference reaches into every stage: how you characterize the drug substance, how you prove it is what you say it is, and how you keep it viable from a frozen master cell bank to a patient dose.

On the discovery and preclinical side, the work that matters is strain isolation and banking, whole-genome sequencing and strain identity, metagenomic and 16S community profiling, and functional characterization (which metabolites the strain produces, how it colonizes, how it behaves in gnotobiotic or humanized-microbiome animal models). Antibiotic-resistance and virulence-factor screening is not optional for a live organism going into people, and the FDA expects a clear safety rationale for each component. GLP toxicology still applies, but the study design has to account for a colonizing, replicating product rather than a fixed dose that clears.

The manufacturing side is where specialist CDMOs separate themselves from generalists most sharply. Many LBP strains are strict anaerobes, so fermentation, harvest, formulation, and fill-finish have to happen under controlled low-oxygen conditions that a conventional biologics suite simply does not have. Then there is lyophilization or other stabilization to keep cells alive on the shelf, enteric or delayed-release encapsulation so the dose survives stomach acid and reaches the gut, and cold-chain logistics throughout. Release testing is its own discipline: viable cell count (CFU or flow-based viability), potency tied to a relevant biological function, strain identity confirmation, and a sterility concept adapted to a product that is deliberately full of live bacteria. A CDMO that does excellent monoclonal antibody work can be the wrong partner here, because none of that anaerobic, live-cell tooling transfers.

How do you choose a CRO or CDMO for Microbiome / Live Biotherapeutic?

The single best filter is whether the vendor has actually made and tested live bacterial products before, ideally ones that reached the clinic. Microbiome manufacturing is unforgiving, and a track record on real LBP programs tells you more than any capability brochure. Walk through the checklist below before you shortlist, and ask for specifics rather than reassurances on each point.

  • Relevant platform and track record: prior work on defined strains, consortia, or donor-derived products, and named LBP programs they have taken through IND or into clinical supply.
  • Anaerobic and live-cell capability: controlled low-oxygen fermentation, harvest, and fill-finish, plus stabilization (lyophilization or equivalent) and the encapsulation needed for gut delivery.
  • Analytical and GxP depth for this modality: validated viability and CFU methods, potency assays tied to function, strain identity by sequencing, residual-DNA and bioburden controls, and a sterility concept that fits a live product, all under GLP and GMP.
  • Capacity and scale: ability to move from research banks to GMP master and working cell banks, and to scale fermentation without losing viability or shifting the strain ratio in a consortium.
  • Regulatory experience: familiarity with the FDA's LBP guidance and CMC expectations, EMA equivalents if you are filing in Europe, and a clean inspection history on live-biologic suites.
  • IP and data ownership: clear terms on who owns strains, banks, process know-how, and the characterization data, especially when the vendor contributes a manufacturing platform.
  • Cold chain and supply continuity: stability data behind the storage claim, and a credible answer for backup capacity if a single anaerobic suite goes down.

Frequently asked questions

What is the difference between a microbiome product and a live biotherapeutic product (LBP)?
In regulatory terms the FDA defines a live biotherapeutic product as a biological product that contains live organisms, such as bacteria, and is intended to prevent, treat, or cure a disease, and is not a vaccine. "Microbiome" is the broader scientific umbrella covering the whole community of organisms and any therapy that targets it, which can include LBPs, fecal-derived products, prebiotics, or even small molecules that modulate the microbiome. Most live-bacteria drug programs you would source CRO and CDMO services for are LBPs, so the two terms get used interchangeably even though they are not exactly the same thing.
Why can't a standard biologics CDMO manufacture our live bacterial product?
Because the tooling is fundamentally different. Many therapeutic strains are strict anaerobes that die on exposure to oxygen, so fermentation, harvest, formulation, and fill-finish all need controlled low-oxygen environments that a conventional monoclonal antibody or cell-culture suite does not have. On top of that you need live-cell stabilization (usually lyophilization), enteric encapsulation for gut delivery, viability-based release testing rather than the usual protein assays, and a sterility approach designed for a product that is intentionally full of live bacteria. A generalist CDMO without dedicated anaerobic and LBP capability can run a perfectly good antibody line and still be unable to make your drug.
What release and characterization tests does a live biotherapeutic need?
The core set is viable cell count (CFU plating or a validated flow-cytometry viability method), potency tied to a relevant biological function rather than just live count, strain identity confirmed by whole-genome or marker sequencing, and purity and safety checks including bioburden, absence of specified contaminants, antibiotic-resistance gene screening, and a sterility concept adapted to a live product. For a consortium you also have to confirm the ratio of strains, because the community composition is part of the drug definition. These methods need to be validated, which is exactly the kind of analytical depth a specialist LBP CDMO or CRO brings that a generalist usually does not.
How does FDA regulate microbiome and live biotherapeutic products?
In the US, LBPs are regulated as biological products and go through the IND then BLA pathway, overseen by CBER. The FDA has published specific guidance on early clinical-trial CMC information for LBPs, which sets expectations for strain characterization, banking, manufacturing controls, and safety data such as antibiotic-resistance and virulence screening. The agency expects a clear rationale for every organism in the product. A CRO or CDMO that has navigated LBP-specific INDs before is worth a lot here, because the CMC section for a living drug substance does not look like a small-molecule or even a typical biologic filing.
Who owns the strains and process know-how when we outsource manufacturing?
Settle this in writing before any work starts. In a clean arrangement the sponsor owns the proprietary strains, the master and working cell banks made from them, and the characterization data generated under the program. The grey area is the manufacturing process: a CDMO with its own fermentation or stabilization platform may claim rights to platform-level know-how. Make sure the contract separates your strain and product IP from their background platform, and spell out how banks, data, and the validated process transfer to you or to a second-source manufacturer later. Ambiguous IP terms on a living drug substance are a real risk, not a formality.
How do you source multiple microbiome vendors without managing separate contracts?
A live biotherapeutic program often needs more than one partner: a CRO for strain characterization and metagenomic work, a tox CRO for GLP studies, and a specialist CDMO for anaerobic GMP manufacturing and fill-finish. Contracting and paying each one separately is slow and creates several points of administrative friction. Through BioBridgeX you source and compare these vendors, then contract once: one contract, one purchase order, and one invoice across every vendor, with BioBridgeX acting as the neutral vendor of record. The platform is free for buyers; vendors pay a flat 2% fee, so quotes are not padded with buyer-side markups.

Source Microbiome / Live Biotherapeutic work with one contract

Compare transparent quotes from qualified Microbiome / Live Biotherapeutic CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes